Minapharm produces high-quality, small-molecule products using the latest manufacturing technologies. By leveraging its expertise in chemical synthesis and biological target identification, the company provides innovative solutions to address unmet medical needs. Its commitment to quality and regulatory compliance ensures it is able to meet the highest standards for safety and efficacy.
Minapharm distinguishes itself in the pharmaceutical landscape through its broad portfolio and by being a pioneer in introducing first-to-launch branded generics, ensuring accessibility to high-quality medications. Minapharm also stands at the forefront of pharmaceutical innovation with its advanced galenic formulations, reflecting a commitment to developing sophisticated drug delivery systems and enhancing the effectiveness of treatments. The strategic emphasis on line extensions further underscores the company's dedication to continuous improvement, offering an expanded range of dosage forms to meet evolving patient
requirements. Moreover, Minapharm strategically augments its portfolio through the incorporation of in-licensed brands, enabling the company to provide a wider spectrum of high-quality pharmaceutical solutions.
First generation biologics are proteins that resemble naturally occurring proteins in the body. Minapharm has four self-developed 1st generation biologics in its portfolio — IFNG, Hirudin, FSH, and PTH — which the company markets and manufactures.
As the first and largest biologics and biosimilars manufacturer in MEA, Minapharm offers a wide range of recombinant proteins, which use various expression systems. Minapharm uses all common cell line types for manufacturing of proteins and viral vector vaccines and can manufacture drug substance with 10,000’s of Liters capacity and the respective F&F capacities (vials, solution, and lyophilized, pre-filled injections). Minapharm has decades of cold-chain experience.
Second generation biologics are more complex proteins such as monoclonal antibodies (mAbs). Minapharm’s diverse portfolio of self-developed mAbs represent a significant leap forward in the realm of therapeutic proteins. Through redefined manufacturing processes and strategic collaborations, these hold immense promise in reshaping the landscape of healthcare by offering targeted treatment options for immuno-oncology and autoimmunity. This innovative pipeline seeks to redefine the conventional cost barriers associated with mAbs, making these cutting-edge treatments more accessible to patients in the MEA region.
Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing approved reference biologics. They offer a cost-effective alternative to expensive branded biologics, making life-saving treatments more accessible to patients, which is especially crucial for the African continent.
Aligning with its mission, Minapharm recognizes the pressing need for affordable healthcare innovations in Africa and is leveraging its robust biological infrastructure, cutting-edge technologies, and technical expertise to develop and license biosimilars for regional manufacturing and supply.
Cell and gene therapy is at the frontier of ground-breaking treatments for rare and often incurable diseases. By correcting errors in the genome, nucleic acid and cell-based therapies can cure the underlying genetic cause of diseases as well as redirect the patient's immune system to treat previously untreatable diseases such as cancer.
There are currently 2500 ongoing CGT clinical trials worldwide, none of which are being conducted in Africa. The primary obstacles have been a lack of regional manufacturing capacity and regulatory transparency. As a result, such therapies have not yet been approved in the region. Nevertheless, a predicted compound annual growth rate of 30 percent by 2025 for the CGT industry has sparked a growing interest in the region.
Minapharm is well positioned to alleviate significant barriers to CGT manufacture and development in the region. The company produces its own CGT products for the MEA region and uses its proprietary technologies to help secure new contracts.
Africa's heavy reliance on imported vaccines, as evidenced during the COVID-19 pandemic, highlights the urgent need for regional vaccine production. Minapharm, with its extensive experience in biologics production and a wide range of drug substance and drug product manufacturing platforms including yeast, mammalian, and viral vector technologies, alongside the expertise and proprietary technologies from ProBioGen, holds a strategic position to address this pressing need.
Equipped with infrastructure, advanced technology, and technical research and process development capabilities, Minapharm is primed for technology transfers and vaccine manufacturing tailored to Africa's priorities. This positions Minapharm as a vital player in ensuring a consistent and widespread supply of priority vaccines across the African continent, strengthening regional health security. Minapharm formed an extensive network in the vaccine landscape, ranging from partnerships with vaccine players in the industry to collaborative agreements with world-class organizations.
